#### Check for updates

### OPEN ACCESS

EDITED BY Jianguo Tang, Fudan University, China

REVIEWED BY Fangdie Ye, Fudan University, China Zhizhou Wang, Dalian Medical University, China

\*CORRESPONDENCE Ting Yu Imig njmuyt@163.com Hua Li Imig lihua\_gx@ymun.edu.cn

<sup>†</sup>These authors have contributed equally to this work and share first authorship

RECEIVED 21 September 2023 ACCEPTED 06 November 2023 PUBLISHED 01 December 2023

#### CITATION

Zhu F, Zhang P, Liu Y, Bao C, Qian D, Ma C, Li H and Yu T (2023) Mendelian randomization suggests a causal relationship between gut dysbiosis and thyroid cancer. *Front. Cell. Infect. Microbiol.* 13:1298443. doi: 10.3389/fcimb.2023.1298443

#### COPYRIGHT

© 2023 Zhu, Zhang, Liu, Bao, Qian, Ma, Li and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Mendelian randomization suggests a causal relationship between gut dysbiosis and thyroid cancer

Feng Zhu<sup>1,2†</sup>, Pengpeng Zhang<sup>3,4†</sup>, Ying Liu<sup>5†</sup>, Chongchan Bao<sup>6†</sup>, Dong Qian<sup>5</sup>, Chaoqun Ma<sup>5</sup>, Hua Li<sup>7\*</sup> and Ting Yu<sup>1\*</sup>

<sup>1</sup>Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China, <sup>2</sup>Department of Gastroenterology, The First People's Hospital of Kunshan, Suzhou, China, <sup>3</sup>Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, <sup>4</sup>Department of Thoracic Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China, <sup>6</sup>Department of General Surgery, Affiliated Hospital of Nanjing University of TCM, Jiangsu Province Hospital of TCM, Nanjing, China, <sup>6</sup>Department of Breast and Thyroid Surgery, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China, <sup>7</sup>Department of General Surgery, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China

**Background:** Alterations in gut microbiota composition and function have been linked to the development and progression of thyroid cancer (TC). However, the exact nature of the causal relationship between them remains uncertain.

**Methods:** A bidirectional two-sample Mendelian randomization (TSMR) analysis was conducted to assess the causal connection between gut microbiota (18,340 individuals) and TC (6,699 cases combined with 1,613,655 controls) using data from a genome-wide association study (GWAS). The primary analysis used the inverse-variance weighted (IVW) method to estimate the causal effect, with supplementary approaches including the weighted median, weighted mode, simple mode, and MR-Egger. Heterogeneity and pleiotropy were assessed using the Cochrane Q test, MR-Egger intercept test, and MR-PRESSO global test. A reverse TSMR analysis was performed to explore reverse causality.

**Results:** This study identified seven microbial taxa with significant associations with TC. Specifically, the genus *Butyrivibrio* (OR: 1.127, 95% CI: 1.008-1.260, p = 0.036), *Fusicatenibacter* (OR: 1.313, 95% CI: 1.066-1.618, p = 0.011), *Oscillospira* (OR: 1.240, 95% CI: 1.001-1.536, p = 0.049), *Ruminococcus2* (OR: 1.408, 95% CI: 1.158-1.711, p < 0.001), *Terrisporobacter* (OR: 1.241, 95% CI: 1.018-1.513, p = 0.032) were identified as risk factors for TC, while The genus *Olsenella* (OR: 0.882, 95% CI: 0.787-0.989, p = 0.031) and *Ruminococcaceae UCG004* (OR: 0.719, 95% CI: 0.566-0.914, p = 0.007) were associated with reduced TC risk. The reverse MR analysis found no evidence of reverse causality and suggested that TC may lead to increased levels of the genus *Holdemanella* ( $\beta$ : 0.053, 95% CI: 0.012~0.094, p = 0.011) and decreased levels of the order *Bacillales* ( $\beta$ : -0.075, 95% CI: -0.143~-0.006, p = 0.033). No significant bias, heterogeneity, or pleiotropy was detected in this study.

**Conclusion:** This study suggests a potential causal relationship between gut microbiota and TC, providing new insights into the role of gut microbiota in TC. Further research is needed to explore the underlying biological mechanisms.

KEYWORDS

Mendelian randomization, bidirectional, causal relationship, gut dysbiosis, thyroid cancer

### **1** Introduction

Thyroid cancer (TC) is the most common form of endocrine malignant neoplasm, with steadily increasing global incidence over recent decades (Kitahara and Sosa, 2016; Lin et al., 2021; Siegel et al., 2023). It is projected to become the fourth most prevalent cancer worldwide by 2030 (Kim et al., 2020). TC, while generally having a favorable survival rate, imposes significant healthcare costs and long-term quality of life challenges for patients (Lubitz et al., 2014; Hedman et al., 2016; Wang et al., 2018). As a result, TC has become a global health concern.

The exact pathogenesis of TC remains unclear, but it is widely accepted that genetic and environmental factors play significant roles in its development (Kim et al., 2020). The maintenance of a healthy gut microbiota composition is crucial for overall health, particularly for the immune and endocrine systems (Li et al., 2019). Recent research has highlighted the intricate connection between gut microbiota and the thyroid gland, often referred to as the gutthyroid axis (Su et al., 2020; Sagaram et al., 2022; Biscarini et al., 2023; Cao et al., 2023). Dysbiosis, or an imbalance in gut microbiota composition and function, has been implicated in the etiology and progression of thyroid disorders, including TC (Zhang et al., 2019; Samimi and Haghpanah, 2020; Li et al., 2021; Ishaq et al., 2022; Lu et al., 2022). However, studies investigating the link between gut microbiota and TC have produced inconsistent findings, and the precise role of gut microbiota in TC development remains uncertain. It is unclear whether they play a causal role or are simply a consequence of shared risk factors.

Mendelian randomization (MR) is a novel statistical approach that allows researchers to assess causal relationships in potential exposure-outcome pathways. MR uses genetic variants as instrumental variables to act as proxies for exposure phenotypes, making it less susceptible to the influence of environmental confounders and reverse causality (Xu et al., 2021). While MR has been extensively used to study the relationship between gut microbiota and thyroid disorders, limited evidence exists regarding the causal effects of gut microbiota on TC. This study conducted a comprehensive two-sample Mendelian randomization (TSMR) analysis to investigate the potential causal connection between gut microbiota and TC, providing insights into the role of gut microbiota in TC pathogenesis and potential therapeutic interventions.

# 2 Materials and methods

### 2.1 Study design

This study employed a TSMR approach to investigate the causal relationship between gut microbiota and thyroid cancer across multiple taxonomic levels, including 9 phyla, 16 classes, 20 orders, 35 families, and 131 genera. Figure 1 depicted the study design and illustrated the essential MR assumptions (Bowden et al., 2015; Sanderson et al., 2019): (1) the IVs should exhibit a strong and consistent association with gut microbiota, (2) IVs should not be associated with any confounding factors, and (3) IVs solely influenced thyroid cancer via the pathway of the exposure factors.

### 2.2 Data sources

Genetic data on gut microbiota were obtained from a comprehensive meta-analysis of genome-wide association studies (GWAS) involving 18,340 individuals from 24 cohorts, conducted by the MiBioGen consortium (www.mibiogen.org) (Kurilshikov et al., 2021). A total of 211 bacterial taxa and 122,110 associated single nucleotide polymorphisms (SNPs) were identified, with 15 bacterial taxa lacking specific species names excluded. GWAS metaanalyses on thyroid cancer were sourced from the Global Biobank Meta-Analysis Initiative (GBMI), which included 6,699 cases and 1,613,655 controls (Zhou et al., 2022). Ethical approval was obtained for the use of the original data.

### 2.3 The selection of instrumental variables

Firstly, to enhance the number of available SNPs, a lenient threshold of  $p < 1 \times e^{-5}$  was employed (Long et al., 2023; Yu et al., 2023). Similarly, in the reverse analysis investigating the impact of thyroid cancer on the gut microbiota, IVs were chosen with a loose cutoff of  $p < 5 \times e^{-8}$ . Subsequently, linkage disequilibrium (LD) was employed to evaluate the existence of gene linkage among these SNPs, employing an  $r^2$  value of 0.001 and a window size of 10,000 kb. The formula  $F = beta^2_{exposure}/se^2_{exposure}$  and  $R^2 = 2\times(1-MAF)\times MAF\times beta^2$  were utilized to assess the statistical significance of SNPs, and the SNPs with weak associations (F <



variables; LD, linkage disequilibrium; SNP, single nucleotide polymorphism; MR-PRESSO, MR pleiotropy residual sum and outlier. Figure 1 was produced using Figdraw (https://www.figdraw.com/static/index.html).

10) were eliminated (Xie et al., 2023). During the coordination process of the exposure and outcome data, incompatible and palindromic SNPs were eliminated. Furthermore, potential pleiotropic confounders were identified using the Phenoscanner database (http://www.phenoscanner.medschl.cam.ac.uk/) (Kamat et al., 2019). The findings of our investigation indicated that eight SNPs exhibited associations with potential risk factors for thyroid cancer. Specifically, rs17379710, rs113379006 and rs10931481 were found to be linked with "Treatment with levothyroxine sodium" or "Self-reported hypothyroidism or myxoedema," while rs12124567, rs1035691, rs6489992, rs17708276, and rs113379006 demonstrated an association with diastolic blood pressure (Huang et al., 2022), which were all excluded from the current study.

# 2.4 MR analysis

In this study, we utilized a bidirectional TSMR analysis to explore the causal connection between the gut microbiome and thyroid cancer, employing four common MR methods: inversevariance-weighted (IVW), weighted median (WM), MR-Egger regression, and Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO). Additionally, we employed the Wald ratio test to examine features exclusively encompassing one IV (Burgess et al., 2017). The IVW approach served as the primary method for estimating the causal effect, aiming to ascertain the cumulative impact of all SNPs (Burgess et al., 2013). The WM method is endowed with the capacity to integrate information from multiple genetic variants, yielding a singular causal estimation, provided that at least fifty percent of the weight originates from valid IVs (Bowden et al., 2016). The MR-Egger method, grounded on the assumption of InSIDE, can yield unbiased estimates of causal relationships, even in scenarios where all instrumental SNPs are invalidated due to pleiotropy (Bowden et al., 2015). It is worth noting that if these methods yield inconsistent outcomes, we will accord priority to IVW as the principal result.

Furthermore, we conducted a set of sensitivity analyses to ensure the validity and dependability of our findings. We applied the MR-PRESSO global test and the MR Egger intercept test to evaluate the presence of global horizontal pleiotropy in the IVs. A pvalue surpassing 0.05 would indicate the absence of statistically significant horizontal pleiotropy (Verbanck et al., 2018). In this study, we employed Cochran's Q statistic (MR-IVW) to detect heterogeneity, where a p-value exceeding 0.05 signified the absence of heterogeneity (Hemani et al., 2018). Simultaneously, we performed a leave-one-out sensitivity analysis on the significant results to ascertain whether a single SNP was accountable for the observed causal relationship in the TSMR analysis (Kurilshikov et al., 2021). Additionally, we executed the reverse TSMR procedure in accordance with the previously mentioned TSMR analysis. The study design adhered to the STROBE-MR (Strengthening the Reporting of Observational studies in Epidemiology - Mendelian randomization) guideline (Skrivankova et al., 2021).

### 2.5 Statistical analysis

For a more stringent interpretation of the causal link, the Bonferroni-adjusted significance criterion was applied, considering the feature level of each bacteria: genera: 0.05/119 ( $4.2 \times 10-4$ ), families: 0.05/32 ( $1.56 \times 10-3$ ), orders: 0.05/20 ( $2.5 \times 10-3$ ), classes: 0.05/16 ( $3.1 \times 10-3$ ), and phyla: 0.05/9 ( $5.5 \times 10-3$ ) (Shi et al., 2023). Microbiomes exhibiting *p* values below 0.05/n were identified as having a notably likely connection with thyroid cancer, while those falling within the range of 0.05 to the adjusted value were considered to have a nominal causal influence (Georgakis et al., 2019; Yu et al., 2021; Long et al., 2023). All computations were carried out employing TwoSampleMR (version 0.5.6) and R version 4.3.0 (R Foundation for Statistical Computing).

# **3** Findings

# 3.1 The influences of gut microbiota on TC patients

Upon excluding SNPs linked to potential TC risk factors, a total of 1,479 IVs were included in the examination of gut microbiota's causal effects on TC (Supplementary Table 1). The F-statistics for all IVs exceeded 10, indicating the absence of weak instrument bias (Supplementary Table 2).

As depicted in Figure 2, employing the IVW method, it was revealed that a genetically projected higher abundance of the genus *Butyrivibrio* (OR: 1.127, 95% CI: 1.008-1.260, p = 0.036), *Fusicatenibacter* (OR: 1.313, 95% CI: 1.066-1.618, p = 0.011), *Oscillospira* (OR: 1.240, 95% CI: 1.001-1.536, p = 0.049),



MR analysis of gut microbiota on thyroid cancer. (A) From outside to inside, the P values of IVW, MR Egger, WM, WMODE, and WR are represented, respectively. (B) Forest plots of MR results for seven gut microbiota taxa on thyroid cancer. MR, Mendelian Randomization; NSNP, number of SNPs; IVW, inverse-variance weighted; WM, weighted median; WMODE, weighted mode; WR, Wald Ratio; OR, odds ratio.

*Ruminococcus2* (OR: 1.408, 95% CI: 1.158-1.711, p < 0.001), *Terrisporobacter* (OR: 1.241, 95% CI: 1.018-1.513, p = 0.032) was linked to an increased TC risk. Conversely, heightened genetically projected levels of the genus *Olsenella* (OR: 0.882, 95% CI: 0.787-0.989, p = 0.031) and *Ruminococcaceae UCG004* (OR: 0.719, 95% CI: 0.566-0.914, p = 0.007) were associated with a decreased risk of TC. Figure 3 illustrates the scatterplot depicting the gut microbiome's causal effect on TC.

The sensitivity analyses in this study did not yield any indications of heterogeneity, as revealed by Cochrane's Q test of the IVW method (Table 1). Additionally, employing the leave-oneout method did not pinpoint any instances where a single SNP significantly impacted the observed outcomes across the seven positive findings (Supplementary Figure 1). Furthermore, as shown in Table 1, the MR-Egger intercept test and MR PRESSO global test affirmed the absence of horizontal pleiotropy.

# 3.2 Reverse analysis of TSMR: influence of TC on gut microbiota

To explore the potential causative influence of TC on gut microbiota, 19 TC-associated SNPs from the GBMI were utilized as instrumental variables (IVs) (Supplementary Table 5). Utilizing the IVW method, an elevation in the abundance of genus *Holdemanella* was observed following the onset of TC, while TC was linked to a reduction in the levels of order *Bacillales* (Table 2). Figure 4 illustrates the scatterplot depicting the causal estimates of TC exposure on specific gut microbiota. Furthermore, it was ascertained that the IVs were devoid of any indications of weak instrument bias or heterogeneity statistics, and no evidence of horizontal pleiotropy was identified between the IVs and the gut microbiota (Supplementary Table 6). Leave-one-out analysis indicated that none of the SNPs significantly impacted the MR outcomes (Supplementary Figure 2).

## 4 Discussion

To the best of our knowledge, a thorough and comprehensive exploration of the links between gut microbiota and TC, utilizing publicly accessible genetic data, has been conducted for the first time. The results of this investigation indicate that, at the level of genera, an increase in the abundance of *Butyrivibrio*, *Fusicatenibacter*, *Oscillospira*, *Ruminococcus2*, and *Terrisporobacter* may contribute to an elevated risk of TC, while heightened levels of *Olsenella* and *Ruminococcaceae UCG004* are associated with a reduced TC risk. In the subsequent reverse MR analysis, it was observed that the onset of TC might lead to a decrease in the abundance of genus *Holdemanella* and an increase in the level of order *Bacillales*.

Gut dysbiosis is a common phenomenon observed in individuals with thyroid disorders. Also, it has been the subject of recent research providing compelling evidence of the crucial interplay between gut microbiota and the thyroid gland, thus suggesting the presence of a robust gut-thyroid axis (Lerner et al., 2017; Liu et al., 2022). It has been reported that the gut microbiota and its metabolites have the potential to influence thyroid hormone homeostasis by triggering immune-inflammatory responses, modifying iodothyronine metabolism, and affecting the absorption of thyroid-associated micronutrients (Jiang et al., 2022). Multiple studies have been conducted to probe into the



Scatter plots of causal estimates of exposure (specific gut microbiota) on thyroid cancer. (A) *Genus Butyrivibrio*; (B) *Genus Fusicatenibacter*; (C) *Genus Oscillospira*; (D) *Genus Ruminococcus2*; (E) *Genus Terrisporobacter*; (F) *Genus Olsenella*; (G) *Genus Ruminococcaceae UCG004*. MR, Mendelian Randomization.

Exposure	Cochrane Q statistic	MR Egger intercept	MR Egger intercept pval	MR PRESSO Global Test pval	Outliers
Genus Fusicatenibacter	0.297	0.010	0.722	0.453	NA
Genus Olsenella	0.657	0.032	0.283	0.328	NA
Genus Oscillospira	0.702	-0.012	0.794	0.669	NA
Genus <i>Ruminococcaceae</i> UCG004	0.069	-0.038	0.525	0.718	NA
Genus Ruminococcus2	0.618	0.007	0.751	0.109	NA
Genus Terrisporobacter	0.459	-0.043	0.233	0.659	NA
Genus Butyrivibrio	0.075	-0.022	0.584	0.098	NA

TABLE 1 Results of heterogeneity and horizontal pleiotropy for the effect of gut microbiota on thyroid cancer.

MR, mendelian randomization

relationship between gut microbiota and thyroid diseases, including TC. Feng et al. noted that TC patients exhibit a higher level of gut microbiota richness and diversity (a-diversity) compared to a control group of healthy individuals (Feng et al., 2019). Moreover, a predictive model comprising eight genera was employed to distinguish the TC status, encompassing Bacteroides, Lactococcus, Blautia, Eubacterium\_coprostanoligene\_group, Christense nellaceae\_R-7\_group, Ruminococcus\_gnavus\_group, Eubac erium\_hallii\_group, and Lactobacillus (Feng et al., 2019). Similarly, Ishaq HM et al. also indicated significant intestinal bacterial overgrowth in TC patients (Ishaq et al., 2022). However, the study conducted by Lu et al. revealed a marked decrease in the diversity and richness of the gut microbiota in TC patients, with core genera closely linked to lipid metabolism, namely Christensenellaceae\_R-7\_group and Eubacterium\_copros tanoligenes\_group (Lu et al., 2022). In an exploratory cohort involving 90 TC patients and 90 healthy controls, Yu et al. also demonstrated a significant decrease in the richness and diversity of gut microbiota in TC patients (Yu et al., 2022). In their study, TC patients with metastatic lymphadenopathy exhibited a microbial signature characterized by elevated levels of genus Fusobacterium and *Alistipes*, alongside reduced levels of *Hungatella* and *Phascolarctobacterium* (Yu et al., 2022).

Despite the varying findings, it is noteworthy that these studies have reported a decline in the abundance of bacteria producing short-chain fatty acids (SCFAs) in TC patients (Jiang et al., 2022), indicating that the reduction of SCFAs-producing bacteria may contribute to the progression of TC (Yu et al., 2022). In this study, the genus Ruminococcaceae UCG004 (OR: 0.719), a bacterium producing SCFAs, was identified as a protective factor against TC. It has been reported that SCFAs have the ability to inhibit the activity of histone deacetylase, serving as epigenetic modifiers that disrupt the expression of sodium/iodide symporter (NIS) and iodine uptake in TC cells (Samimi and Haghpanah, 2020; Jiang et al., 2022). Thus, SCFAs-producing bacteria like Bifidobacterium and Faecalibacterium prausnitzii have been employed in TC therapy (Lin et al., 2022; Fernandes et al., 2023; Zheng et al., 2023). However, other SCFAs-producing bacteria, including Butyrivibrio (OR: 1.127), Fusicatenibacter (OR: 1.313), Oscillospira (OR: 1.240), and Ruminococcus2 (OR: 1.408), were identified as pathogenic factors for TC, offering a new perspective for future research. Additionally, the genus Terrisporobacter (OR:

TABLE 2 M	R results of	causal	effects	for TC	on	gut	microbiota.
-----------	--------------	--------	---------	--------	----	-----	-------------

Exposure	Outcome	Method	Nsnp	Beta	SE	95% CI	pval
Thyroid Cancer	Genus Holdemanella	MR Egger	19	0.098	0.045	0.009-0.187	0.046
		Weighted median	19	0.073	0.030	0.013 -0.132	0.017
		Inverse variance weighted	19	0.053	0.021	0.012-0.094	0.011
		Simple mode	19	0.086	0.051	-0.015-0.187	0.111
		Weighted mode	19	0.081	0.031	0.021-0.142	0.017
	Order Bacillales	MR Egger	18	0.033	0.072	-0.108-0.173	0.656
		Weighted median	18	-0.043	0.044	-0.130-0.044	0.332
		Inverse variance weighted	18	-0.075	0.035	-0.143~-0.006	0.033
		Simple mode	18	-0.095	0.083	-0.257-0.068	0.268
		Weighted mode	18	-0.033	0.049	-0.130-0.063	0.508

SNP, single nucleotide polymorphism; MR, mendelian randomization; SE, standard error; CI, confidence interval. Bold values represented P<0.05.



1.241), a Gram-positive bacterium belonging to the family *Peptostreptococcaceae*, has also been implicated as a causative agent of TC in the current investigation, with documented potential to cause infections in human beings, especially in postoperative individuals with comorbidities (Wang et al., 2023). However, research on the correlation between the genus *Terrisporobacter* and TC is scarce, necessitating further exploration.

Recently, a considerable body of research has been dedicated to examine the influence of gut dysbiosis on immune responses in cancer (Wang et al., 2020). Genus Olsenella (OR: 0.882) and Ruminococcaceae UCG004 (OR: 0.719), identified as "favorable" intestinal bacteria against TC in this study, have demonstrated potential in the field of tumor immunotherapy (Gopalakrishnan et al., 2018; Mager et al., 2020). According to Gopalakrishnan et al., patients with high diversity and abundance of Ruminococcaceae/ Faecalibacterium exhibited enhanced systemic and anti-tumor immune responses through heightened antigen presentation and improved effector T cell function in both the periphery and the tumor microenvironment (Gopalakrishnan et al., 2018). Furthermore, it has been reported that the genus Olsenella, in combination with Bifidobacterium pseudolongum and Lactobacillus johnsonii, significantly improved the effectiveness of immune checkpoint inhibitors in murine cancer models (Mager et al., 2020). Thus, the present study may offer a fresh perspective on TC immunotherapy, particularly for advanced TC (Laha et al., 2020), from the standpoint of gut microbiota. Overall, limited research has documented the association between these intestinal bacteria and TC, providing new avenues for future studies. Hence, further studies are warranted to explore the specific mechanism of these intestinal bacteria in TC.

This study introduces several innovative elements. Firstly, it adopts a bidirectional TSMR approach based on comprehensive GWAS data to investigate the relationship between gut microbiota and TC, which can mitigate the influence of confounding variables and reverse causation frequently encountered in conventional observational analyses. Moreover, stringent screening criteria for instrumental variables (IVs) were applied, ensuring the absence of heterogeneity or pleiotropy in the outcomes, thereby affirming the robustness of our findings. Subsequently, the analysis on the causal relationship between specific gut microbiota and TC was carried out at various taxonomic levels, ranging from genus to phylum, potentially offering valuable insights for the clinical management of TC. Lastly, our research provides genetic evidence supporting the existence of the gut-thyroid axis, thus emphasizing the strong correlation between gut microbiota and TC.

Nonetheless, it is crucial to acknowledge the limitations of our study. Firstly, the GWAS summary data utilized predominantly consisted of patients of European heritage, potentially leading to biased estimates and limited applicability to diverse ethnic groups. Secondly, our findings did not meet the strict Bonferroni correction. However, it is important to note that the Bonferroni correction is a conservative approach that may result in false negatives (Li et al., 2013; Gupta et al., 2014). Finally, the absence of demographic data in the primary study, such as gender, age, and race, hindered the execution of additional subgroup analyses aimed at attaining more precise correlations.

# 5 Conclusion

Through a bidirectional TSMR approach, our study reveals that the genera *Butyrivibrio*, *Fusicatenibacter*, *Oscillospira*, *Ruminococcus2*, and *Terrisporobacter* may contribute to an increased risk of TC, while elevated levels of *Olsenella* and *Ruminococcaceae* UCG004 are associated with a lower TC risk. The abundance of these specific gut microbiota may potentially serve as novel indicators for TC, and the manipulation of gut microbiota could potentially serve as a viable approach for the management and prevention of TC.

### Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

# Author contributions

FZ: Conceptualization, Data curation, Investigation, Methodology, Writing – original draft, Writing – review & editing. PZ: Conceptualization, Data curation, Investigation, Writing – original draft, Writing – review & editing. YL: Conceptualization, Investigation, Software, Writing – review & editing. CB: Writing – review & editing, Software. DQ: Conceptualization, Writing – original draft. CM: Investigation, Software, Writing – review & editing. HL: Writing – review & editing, Validation, Visualization. TY: Conceptualization, Data curation, Investigation, Methodology, Software, Writing – original draft, Writing – review & editing.

## Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China [grant number: 82000508, TY, PI].

# Acknowledgments

The authors would like to thank the MiBioGen consortium for providing us with a summary of GWAS data related to genetically modified organisms. The authors wish to express their gratitude to the participants and researchers of the Global Biobank Initiative.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

### Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2023.1298443/ full#supplementary-material

### References

Biscarini, F., Masetti, G., Muller, I., Verhasselt, H. L., Covelli, D., Colucci, G., et al. (2023). Gut microbiome associated with graves disease and graves orbitopathy: the INDIGO multicenter european study. *J. Clin. Endocrinol. Metab.* 108 (8), 2065–2077. doi: 10.1210/clinem/dgad030

Bowden, J., Davey, S. G., and Burgess, S. (2015). Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.* 44 (2), 512–525. doi: 10.1093/ije/dyv080

Bowden, J., Davey, S. G., Haycock, P. C., and Burgess, S. (2016). Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. *Genet. Epidemiol.* 40 (4), 304–314. doi: 10.1002/gepi.21965

Burgess, S., Butterworth, A., and Thompson, S. G. (2013). Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet. Epidemiol.* 37 (7), 658–665. doi: 10.1002/gepi.21758

Burgess, S., Small, D. S., and Thompson, S. G. (2017). A review of instrumental variable estimators for Mendelian randomization. *Stat. Methods Med. Res.* 26 (5), 2333–2355. doi: 10.1177/0962280215597579

Cao, J., Wang, N., Luo, Y., Ma, C., Chen, Z., Chenzhao, C., et al. (2023). A cause-effect relationship between Graves' disease and the gut microbiome contributes to the thyroid-gut axis: A bidirectional two-sample Mendelian randomization study. *Front. Immunol.* 14. doi: 10.3389/fimmu.2023.977587

Feng, J., Zhao, F., Sun, J., Lin, B., Zhao, L., Liu, Y., et al. (2019). Alterations in the gut microbiota and metabolite profiles of thyroid carcinoma patients. *Int. J. Cancer* 144 (11), 2728–2745. doi: 10.1002/ijc.32007

Fernandes, A., Oliveira, A., Carvalho, A. L., Soares, R., and Barata, P. (2023). Faecalibacterium prausnitzii in differentiated thyroid cancer patients treated with radioiodine. *Nutrients* 15 (12), 2680. doi: 10.3390/nu15122680

Georgakis, M. K., Malik, R., Bjorkbacka, H., Pana, T. A., Demissie, S., Ayers, C., et al. (2019). Circulating monocyte chemoattractant protein-1 and risk of stroke: meta-

analysis of population-based studies involving 17 180 individuals. Circ. Res. 125 (8), 773-782. doi: 10.1161/CIRCRESAHA.119.315380

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., et al. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science* 359 (6371), 97–103. doi: 10.1126/science.aan4236

Gupta, P. K., Kulwal, P. L., and Jaiswal, V. (2014). Association mapping in crop plants: opportunities and challenges. *Adv. Genet.* 85, 109–147. doi: 10.1016/B978-0-12-800271-1.00002-0

Hedman, C., Djarv, T., Strang, P., and Lundgren, C. I. (2016). Determinants of longterm quality of life in patients with differentiated thyroid carcinoma - a populationbased cohort study in Sweden. *Acta Oncol.* 55 (3), 365–369. doi: 10.3109/ 0284186X.2015.1102965

Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., et al. (2018). The MR-Base platform supports systematic causal inference across the human phenome. *eLife* 7, e34408. doi: 10.7554/eLife.34408

Huang, L., Feng, X., Yang, W., Li, X., Zhang, K., Feng, S., et al. (2022). Appraising the effect of potential risk factors on thyroid cancer: A mendelian randomization study. *J. Clin. Endocrinol. Metab.* 107 (7), e2783–e2791. doi: 10.1210/clinem/dgac196

Ishaq, H. M., Mohammad, I. S., Hussain, R., Parveen, R., Shirazi, J. H., Fan, Y., et al. (2022). Gut-Thyroid axis: How gut microbial dysbiosis associated with euthyroid thyroid cancer. *J. Cancer* 13 (6), 2014–2028. doi: 10.7150/jca.66816

Jiang, W., Lu, G., Gao, D., Lv, Z., and Li, D. (2022). The relationships between the gut microbiota and its metabolites with thyroid diseases. *Front. Endocrinol. (Lausanne)* 13. doi: 10.3389/fendo.2022.943408

Kamat, M. A., Blackshaw, J. A., Young, R., Surendran, P., Burgess, S., Danesh, J., et al. (2019). PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics* 35 (22), 4851–4853. doi: 10.1093/bioinformatics/btz469

Kim, J., Gosnell, J. E., and Roman, S. A. (2020). Geographic influences in the global rise of thyroid cancer. *Nat. Rev. Endocrinol.* 16 (1), 17–29. doi: 10.1038/s41574-019-0263-x

Kitahara, C. M., and Sosa, J. A. (2016). The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 12 (11), 646–653. doi: 10.1038/nrendo.2016.110

Kurilshikov, A., Medina-Gomez, C., Bacigalupe, R., Radjabzadeh, D., Wang, J., Demirkan, A., et al. (2021). Large-scale association analyses identify host factors influencing human gut microbiome composition. *Nat. Genet.* 53 (2), 156–165. doi: 10.1038/s41588-020-00763-1

Laha, D., Nilubol, N., and Boufraqech, M. (2020). New therapies for advanced thyroid cancer. *Front. Endocrinol. (Lausanne)* 11. doi: 10.3389/fendo.2020.00082

Lerner, A., Jeremias, P., and Matthias, T. (2017). Gut-thyroid axis and celiac disease. Endocr. Connect 6 (4), R52–R58. doi: 10.1530/EC-17-0021

Li, A., Li, T., Gao, X., Yan, H., Chen, J., Huang, M., et al. (2021). Gut microbiome alterations in patients with thyroid nodules. *Front. Cell Infect. Microbiol.* 11. doi: 10.3389/fcimb.2021.643968

Li, H., Peng, Z., Yang, X., Wang, W., Fu, J., Wang, J., et al. (2013). Genome-wide association study dissects the genetic architecture of oil biosynthesis in maize kernels. *Nat. Genet.* 45 (1), 43–50. doi: 10.1038/ng.2484

Li, Y., Su, X., Zhang, L., Liu, Y., Shi, M., Lv, C., et al. (2019). Dysbiosis of the gut microbiome is associated with CKD5 and correlated with clinical indices of the disease: a case-controlled study. *J. Transl. Med.* 17 (1), 228. doi: 10.1186/s12967-019-1969-1

Lin, B., Zhao, F., Liu, Y., Wu, X., Feng, J., Jin, X., et al. (2022). Randomized clinical trial: probiotics alleviated oral-gut microbiota dysbiosis and thyroid hormone withdrawal-related complications in thyroid cancer patients before radioiodine therapy following thyroidectomy. *Front. Endocrinol. (Lausanne)* 13. doi: 10.3389/ fendo.2022.834674

Lin, L., Li, Z., Yan, L., Liu, Y., Yang, H., and Li, H. (2021). Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden 1990-2019. *J. Hematol. Oncol.* 14 (1), 197. doi: 10.1186/s13045-021-01213-z

Liu, Q., Sun, W., and Zhang, H. (2022). Interaction of gut microbiota with endocrine homeostasis and thyroid cancer. *Cancers (Basel)* 14 (11). doi: 10.3390/cancers14112656

Long, Y., Tang, L., Zhou, Y., Zhao, S., and Zhu, H. (2023). Causal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation study. *BMC Med.* 21 (1), 66. doi: 10.1186/s12916-023-02761-6

Lu, G., Yu, X., Jiang, W., Luo, Q., Tong, J., Fan, S., et al. (2022). Alterations of gut microbiome and metabolite profiles associated with anabatic lipid dysmetabolism in thyroid cancer. *Front. Endocrinol. (Lausanne)* 13. doi: 10.3389/fendo.2022.893164

Lubitz, C. C., Kong, C. Y., Mcmahon, P. M., Daniels, G. H., Chen, Y., Economopoulos, K. P., et al. (2014). Annual financial impact of well-differentiated thyroid cancer care in the United States. *Cancer-Am. Cancer Soc* 120 (9), 1345–1352. doi: 10.1002/cncr.28562

Mager, L. F., Burkhard, R., Pett, N., Cooke, N., Brown, K., Ramay, H., et al. (2020). Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. *Science* 369 (6510), 1481–1489. doi: 10.1126/science.abc3421

Sagaram, M., Royer, A. J., Hu, H., Rajhans, A., Parthasarathy, R., Krishnasamy, S. S., et al. (2022). Illustration of gut-thyroid axis in alcohol use disorder: interplay of gut dysfunction, pro-inflammatory responses, and thyroid function. *Cells* 11 (19), 3100. doi: 10.3390/cells11193100

Samimi, H., and Haghpanah, V. (2020). Gut microbiome and radioiodine-refractory papillary thyroid carcinoma pathophysiology. *Trends Endocrinol. Metab.* 31 (9), 627–630. doi: 10.1016/j.tem.2020.03.005

Sanderson, E., Davey, S. G., Windmeijer, F., and Bowden, J. (2019). An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *Int. J. Epidemiol.* 48 (3), 713–727. doi: 10.1093/ije/dyy262

Shi, H., Zhao, T., Geng, R., Sun, L., and Fan, H. (2023). The associations between gut microbiota and chronic respiratory diseases: a Mendelian randomization study. *Front. Microbiol.* 14. doi: 10.3389/fmicb.2023.1200937

Siegel, R. L., Miller, K. D., Wagle, N. S., and Jemal, A. (2023). Cancer statistic. CA Cancer J. Clin. 73 (1), 17–48. doi: 10.3322/caac.21763

Skrivankova, V. W., Richmond, R. C., Woolf, B., Yarmolinsky, J., Davies, N. M., Swanson, S. A., et al. (2021). Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. *JAMA* 326 (16), 1614–1621. doi: 10.1001/jama.2021.18236

Su, X., Zhao, Y., Li, Y., Ma, S., and Wang, Z. (2020). Gut dysbiosis is associated with primary hypothyroidism with interaction on gut-thyroid axis. *Clin. Sci. (Lond)* 134 (12), 1521–1535. doi: 10.1042/CS20200475

Verbanck, M., Chen, C. Y., Neale, B., and Do, R. (2018). Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat. Genet.* 50 (5), 693–698. doi: 10.1038/s41588-018-0099-7

Wang, J., Luo, R., Zhao, X., Xia, D., Liu, Y., Shen, T., et al. (2023). Association between gut microbiota and primary ovarian insufficiency: a bidirectional two-sample Mendelian randomization study. *Front. Endocrinol. (Lausanne)* 14. doi: 10.3389/ fendo.2023.1183219

Wang, T., Jiang, M., Ren, Y., Liu, Q., Zhao, G., Cao, C., et al. (2018). Health-related quality of life of community thyroid cancer survivors in Hangzhou, China. *Thyroid* 28 (8), 1013–1023. doi: 10.1089/thy.2017.0213

Wang, Y., Zhang, C., Lai, J., Zhao, Y., Lu, D., Bao, R., et al. (2020). Noninvasive PET tracking of post-transplant gut microbiota in living mice. *Eur. J. Nucl. Med. Mol. Imaging* 47 (4), 991–1002. doi: 10.1007/s00259-019-04639-3

Xie, J., Huang, H., Liu, Z., Li, Y., Yu, C., Xu, L., et al. (2023). The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study. *Hepatology* 77 (3), 949–964. doi: 10.1002/hep.32728

Xu, Q., Ni, J. J., Han, B. X., Yan, S. S., Wei, X. T., Feng, G. J., et al. (2021). Causal relationship between gut microbiota and autoimmune diseases: A two-sample mendelian randomization study. *Front. Immunol.* 12. doi: 10.3389/fimmu.2021.746998

Yu, H., Wan, X., Yang, M., Xie, J., Xu, K., Wang, J., et al. (2023). A large-scale causal analysis of gut microbiota and delirium: A Mendelian randomization study. *J. Affect. Disord.* 329, 64–71. doi: 10.1016/j.jad.2023.02.078

Yu, X. H., Yang, Y. Q., Cao, R. R., Bo, L., and Lei, S. F. (2021). The causal role of gut microbiota in development of osteoarthritis. *Osteoarthritis Cartilage* 29 (12), 1741–1750. doi: 10.1016/j.joca.2021.08.003

Yu, X., Jiang, W., Kosik, R. O., Song, Y., Luo, Q., Qiao, T., et al. (2022). Gut microbiota changes and its potential relations with thyroid carcinoma. J. Adv. Res. 35, 61–70. doi: 10.1016/j.jare.2021.04.001

Zhang, J., Zhang, F., Zhao, C., Xu, Q., Liang, C., Yang, Y., et al. (2019). Dysbiosis of the gut microbiome is associated with thyroid cancer and thyroid nodules and correlated with clinical index of thyroid function. *Endocrine* 64 (3), 564–574. doi: 10.1007/s12020-018-1831-x

Zheng, L., Zhang, L., Tang, L., Huang, D., Pan, D., Guo, W., et al. (2023). Gut microbiota is associated with response to (131)I therapy in patients with papillary thyroid carcinoma. *Eur. J. Nucl. Med. Mol. Imaging* 50 (5), 1453–1465. doi: 10.1007/ s00259-022-06072-5

Zhou, W., Kanai, M., Wu, K. H., Rasheed, H., Tsuo, K., Hirbo, J. B., et al. (2022). Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease. *Cell Genom* 2 (10), 100192. doi: 10.1016/j.xgen.2022.100192